Heterocyclidene acetamide derivative
    2.
    发明授权
    Heterocyclidene acetamide derivative 有权
    杂环亚乙酰胺衍生物

    公开(公告)号:US07910751B2

    公开(公告)日:2011-03-22

    申请号:US11988659

    申请日:2006-07-24

    IPC分类号: C07D313/00 C07D309/00

    摘要: A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X1 represents O, —NR3—, or —S(O)r-; X2 represents a methylene group, O, —NR3—, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

    摘要翻译: 由式(I')表示的化合物:其中m,n和p各自表示0〜2; q表示0或1; R1表示卤素,烃基,杂环基,烷氧基,烷氧基羰基, 氨磺酰基,CN基,NO 2基等; R 2表示卤素,氨基,烃基,芳香族杂环基或氧代基; X 1表示O,-NR 3 - 或-S(O) R 2; X 2表示亚甲基,O,-NR 3 - 或-S(O)r - ; Q'表示杂芳基,杂芳基烷基,取代的芳基或芳烷基; 环或杂芳环;波浪线表示E-异构体或Z-异构体),化合物的盐或化合物或其盐的溶剂合物。 药物组合物和瞬时受体电位型I(TRPV1)受体拮抗剂各自含有化合物,化合物的盐和化合物或其盐的溶剂合物中的至少一种作为活性成分。

    Novel Heterocyclidene Acetamide Derivative
    3.
    发明申请
    Novel Heterocyclidene Acetamide Derivative 有权
    新型杂环亚乙基乙酰胺衍生物

    公开(公告)号:US20080287428A1

    公开(公告)日:2008-11-20

    申请号:US11988659

    申请日:2006-07-24

    摘要: A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X1 represents O, —NR3—, or —S(O)r-; X2 represents a methylene group, O, —NR3—, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

    摘要翻译: 由式(I')表示的化合物:其中m,n和p各自表示0〜2; q表示0或1; R 1表示卤素,烃基,杂环基, 烷氧基,烷氧基羰基,氨磺酰基,CN基,NO 2 2基等; R 2表示卤素,氨基,烃基, 芳族杂环基或氧代基; X 1表示O,-NR 3 - 或-S(O)r - ; X 2, SUB>表示亚甲基,O,-NR 3 - 或-S(O)r - ; Q'表示杂芳基,杂芳基烷基,取代的芳基或芳烷基 ;环状部分表示芳基环或杂芳基环;波浪线表示E-异构体或Z-异构体),化合物的盐或化合物或其盐的溶剂合物。 药物组合物和瞬时受体电位型I(TRPV1)受体拮抗剂各自含有化合物,化合物的盐和化合物或其盐的溶剂合物中的至少一种作为活性成分。

    Heterocyclidene acetamide derivative
    4.
    发明授权
    Heterocyclidene acetamide derivative 失效
    杂环亚乙酰胺衍生物

    公开(公告)号:US08383839B2

    公开(公告)日:2013-02-26

    申请号:US13008456

    申请日:2011-01-18

    IPC分类号: C07D313/00 C07D309/00

    摘要: A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X1 represents O, —NR3—, or —S(O)r-; X2 represents a methylene group, O, —NR3—, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

    摘要翻译: 由式(I')表示的化合物:其中m,n和p各自表示0〜2; q表示0或1; R1表示卤素,烃基,杂环基,烷氧基,烷氧基羰基, 氨磺酰基,CN基,NO 2基等; R 2表示卤素,氨基,烃基,芳香族杂环基或氧代基; X 1表示O,-NR 3 - 或-S(O) R 2; X 2表示亚甲基,O,-NR 3 - 或-S(O)r - ; Q'表示杂芳基,杂芳基烷基,取代的芳基或芳烷基; 环或杂芳环;波浪线表示E-异构体或Z-异构体),化合物的盐或化合物或其盐的溶剂合物。 药物组合物和瞬时受体电位型I(TRPV1)受体拮抗剂各自含有化合物,化合物的盐和化合物或其盐的溶剂合物中的至少一种作为活性成分。